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Abstract
Yemen is currently experiencing the largest cholera epidemic in recent history. The first cases were 
declared in September 2016, and over 1.1 million cases and 2,300 deaths have since been reported. 
We investigated the phylogenetic relationships, pathogenesis, and antimicrobial resistance 
determinants by sequencing the genomes of Vibrio cholerae isolates from the Yemen epidemic and 
recent isolates from neighbouring regions. These 116 genomic sequences were placed within the 
phylogenetic context of a global collection of 1087 seventh pandemic V. cholerae serogroup O1 
and O139 biotype El Tor isolates [–]. We show that the Yemeni isolates collected during the two 
epidemiological waves of the epidemic [], —the first between September 28th 2016 and April 23rd 
2017 (25,839 suspected cases) and the second beginning on April 24th, 2017 (more than one 
million suspected cases), — are seventh pandemic V. cholerae O1 El Tor (7PET) serotype Ogawa 
isolates from a single sublineage. Using genomic approaches, we link the Yemen epidemic to 
global radiations of pandemic V. cholerae and show that this sublineage originated from South 
Asia and that it caused outbreaks in East Africa before appearing in Yemen. We also show that the 
Yemeni isolates are susceptible to several antibiotics commonly used to treat cholera, and to 
polymyxins, resistance to which is used as a marker of the El Tor biotype.
We investigated the bacterial populations causing the Yemeni cholera epidemic, by 
sequencing 42 V. cholerae O1 serotype Ogawa isolates recovered during this epidemic. 
Thirty-nine of these isolates were collected from cholera patients living in three different 
governorates of Yemen (Fig. 1a, b). They span both waves of the epidemic, having been 
collected between October 5th, 2016 and August 31st, 2017. The three remaining isolates 
were collected from patients from a temporary refugee centre on the Saudi Arabia-Yemen 
border on August 30th, 2017 (Fig. 1b). We also sequenced 74 7PET isolates from South 
Asia, the Middle East, Eastern and Central Africa (Extended Data Fig. 1 and Supplementary 
Table 1). We placed these new isolates in the context of a global collection of 1087 7PET 
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genomic sequences [–] (Supplementary Table 1) and constructed a maximum likelihood 
phylogeny of 1,203 genomes, using 9,986 single-nucleotide variants (SNVs) evenly 
distributed over the non-repetitive, non-recombinant core genome (Fig. 2a).
We also detected a strong temporal signal, making it possible to estimate time-scaled 
phylogenies (Fig. 2b and Extended Data Figs. 2-4), which showed the Yemeni epidemic to 
have originated from a recently emerged 7PET wave 3 clade [] harbouring the cholera toxin 
subunit B gene variant ctxB7 (Fig. 2). All the Yemeni isolates clustered together (median 
pairwise SNV difference of 3 [range of 0-13]) confirming that the two epidemiological 
waves observed during Yemeni epidemic, which had very different clinical attack rates [], 
were produced by a single clone rather than arising from two separate introductions. We 
estimated the date of the most recent common ancestor (MRCA) of the Yemeni isolates at 
January 2016 (95% Bayesian credible interval [CI] September 2015 to June 2016) (Fig. 2b, 
Extended Data Fig. 3, Extended Data Table 1). Our phylogenetic analysis shows that the 
Yemeni isolates are different from those circulating in the Middle East over the last decade, 
such as those isolated in Iraq in 2007 and 2015, and in Iran from 2012 to 2015 (Fig. 2a). 
These Middle Eastern isolates also belong to 7PET wave 3, but are attributed to different 
sublineages on the phylogenetic tree, and were imported from South Asia on two separate 
occasions. The Yemeni isolates are most closely related to isolates collected from outbreaks 
in Eastern Africa (Kenya, Tanzania [] and Uganda []) from 2015 to 2016 (Fig. 2). 
Collectively, these isolates belong to a new sublineage, T13, corresponding to the most 
recent, newly identified introduction of 7PET into East Africa. All these T13 isolates are 
different from those previously recovered in West or East Africa (sublineages T12 and T10, 
respectively) (Fig. 2). Our data suggest that the 7PET wave 3 clade containing all isolates 
with the ctxB7 allele, first emerged in South Asia in the early 2000s (Fig. 2b), consistent 
with the first detection of ctxB7 isolates in Kolkata, India in 2006 []. This ctxB7 clade has 
been exported to areas outside Asia on at least three separate occasions: West Africa (T12 
introduction event) [] in 2008 (estimates with 95% CI), Haiti in 2010 [,], and East Africa 
(T13 introduction event) [] between 2013 and 2014 (estimates with 95% CI) (Fig. 2b and 
Extended Data Fig. 3 and Extended Table 1).
In addition to the ctxB7 allele, all the Yemeni isolates analysed harboured the following 
genomic features (Table 1): (i) the toxin-coregulated pilus gene subunit A gene variant, 
tcpACIRS101 (ii) a deletion (ΔVC_0495-VC_0512) within Vibrio seventh pandemic island II 
(VSP-II), (iii) and an SXT/R391 integrating conjugating element (ICE) called ICEVchInd5/
ICEVchBan5, which is associated with multiple drug resistance.
Consistent with the genomic evidence, all the Yemeni isolates have a similar narrow 
phenotype of antimicrobial drug resistance to nalidixic acid, the vibriostatic agent O/129, 
and nitrofurantoin (Table 1). Mutations of the DNA gyrase gene, gyrA, resulting in the S83I 
amino-acid substitution, and mutations of the topoisomerase IV gene, parC, resulting in the 
S85L substitution, explain the resistance of the Yemeni isolates to nalidixic acid and their 
decreased susceptibility to ciprofloxacin. A ~10-kb deletion in ICE variable region III 
Supplementary Information
Supplementary Information is linked to the online version of the paper at www.nature.com/nature.
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resulted in the loss of four genes encoding resistance to streptomycin (strA and strB), 
chloramphenicol (floR), and sulfonamides (sul2). The fifth gene of this region, which 
encodes resistance to the vibriostatic agent O/129 (dfrA1), is present in the Yemeni isolates. 
This deletion is not unique, as similar deletions encompassing the strA, strB, floR, and sul2 
genes, flanked by transposase genes, have arisen several times independently in 7PET wave 
3 isolates [,]. The resistance of V. cholerae to nitrofurans is due to the loss of expression of a 
reductase enzyme converting the drug into its active form []. By combining phenotypic and 
genotypic data, we found lesions in the VC_0715 and VC_A0637 genes of nitrofuran-
resistant isolates (Extended Data Table 2). VC_0715 and VC_A0637 encode orthologs of 
the NfsA (52% amino-acid identity) and NfsB (58% amino-acid identity) proteins of E. coli 
K12 (GenBank accession no. NC_000913), respectively. In E. coli, disruption of the 
nitroreductases encoded by these genes confers nitrofuran resistance []. In all 7PET wave 3 
isolates, including the Yemeni isolates, the observed mutations of VC_0715 led to the 
R169C amino-acid substitution, and the mutation of VC_A0637 introduced a premature stop 
codon (Q5Stop) likely to abolish protein function.
The Yemeni isolates were also susceptible to polymyxins. This is an important finding, 
because resistance to polymyxin B has been used as a marker of the V. cholerae O1 El Tor 
biotype since the beginning of the seventh cholera pandemic in 1961 [,]. Unlike the El Tor 
biotype, the classical biotype (responsible for the six previous pandemics) [] is susceptible to 
polymyxin B. Polymyxin resistance is conferred by changes to the lipid A domain of the 
surface lipopolysaccharide, altering its charge [,]. The vprA (VC_1320) gene, disruption of 
which is known to restore susceptibility to polymyxin in 7PET isolates, is required for 
expression of the almEFG operon encoding the genes required for the glycine modification 
of lipid A []. A specific non-synonymous SNV in vprA genes (predicted to result in the 
D89N substitution, Extended Data Fig. 5) was present in 97% (63/65) of polymyxin B-
susceptible isolates (Extended Data Table 2), including all the Yemeni isolates. The first 
polymyxin-susceptible 7PET isolates with this VprA D89N substitution in our dataset were 
identified in South Asia in 2012 (Fig.2b), consistent with microbiological data from Kolkata, 
India, where polymyxin B-susceptible V. cholerae O1 isolates emerged in 2012 and replaced 
polymyxin-resistant strains after 2014 [].
7PET isolates from the ctxB7 clade have been associated with the two largest cholera 
epidemics in recent history. In addition to the ongoing Yemeni epidemic, the introduction of 
this sublineage into Haiti in 2010, in the wake of a devastating earthquake, resulted in one 
million cases and almost 10,000 deaths by 2017 [,]. These two major events highlight the 
threat that cholera continues to pose to public health in vulnerable populations. The United 
Nations (UN) estimates that 16 of the 29 million people in Yemen lack access to clean water 
and basic sanitation, due to the destruction of public and health infrastructures during the 
years of civil conflict []. The complexity of the situation in Yemen before the epidemic was 
set against a backdrop of large acute watery diarrhoea (AWD)/cholera outbreaks across the 
Horn of Africa (Extended Data Fig. 1), which serves as a major hub of migration into 
Yemen [,]. This region, linking Asia to Africa at the southern entrance of the Red Sea, has 
long been a crossroads of trade and communications routes. Several importations of 7PET 
cholera from Asia into the Horn of Africa are likely to have followed this route, such as T3 
in 1970 [].
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The available genomic data for the historical and current importations of the 7PET 
sublineage into Africa are not consistent with a local origin, but instead highlight the 
importance of human-mediated spread of the epidemic 7PET lineage from South Asia. 
However, an inability to obtain samples from countries in this region hampered our efforts to 
reconstruct the routes of transmission in East Africa before the appearance of this strain in 
Yemen more precisely.
In summary, a single recent 7PET sublineage with an unusual antimicrobial resistance 
phenotype is responsible for the cholera epidemic in Yemen. Our study illustrates the key 
role of genomic microbial surveillance and cross-border collaborations in understanding 
global cholera spread and the evolution of virulence and antibiotic resistance determinants.
Methods (ONLINE)
Bacterial isolates
The 116 7PET isolates sequenced in this study are listed in Supplementary Table 1 and 
originated from the collections of the French National Reference Centre for Vibrios and 
Cholera, Institut Pasteur, Paris, France (n=6); the Central Public Health Laboratory of 
Baghdad, Iraq (n=11); the Ministry of Health of South Sudan (n=14); the Pasteur Institute of 
Iran (n=4); the Maharishi Valmiki Infectious Diseases Hospital, Delhi, India (n=29); the 
Central Public Health Laboratory of Sana’a, Yemen (n=39), Amref Health Africa, Kenya 
(n=1), the Kenya Medical Research Institute (n=9), and the Ministry of Health of Saudi 
Arabia (n=3). The isolates were characterized by standard biochemical, culture, and 
serotyping methods [].
Antibiotic susceptibility testing
Antibiotic susceptibility was determined by disc diffusion on Mueller–Hinton agar, in 
accordance with the guidelines of the Antibiogram Committee of the French Society for 
Microbiology []. The following antimicrobial drugs (Bio-Rad, Marnes-la-Coquette, France) 
were tested: ampicillin, cefalotin, cefotaxime, streptomycin, chloramphenicol, erythromycin, 
azithromycin, sulfonamides, trimethoprim-sulfamethoxazole, vibriostatic agent O/129, 
tetracycline, doxycycline, minocycline, nalidixic acid, norfloxacin, ofloxacin, pefloxacin, 
ciprofloxacin, nitrofurantoin, polymyxin B and colistin (polymyxin E). Escherichia coli CIP 
76.24 (ATCC 25922) was used as a control. The minimum inhibitory concentrations (MICs) 
of nalidixic acid and ciprofloxacin were determined by Etests (bioMérieux, Marcy L'Etoile, 
France). The MICs of colistin and polymyxin B were determined with custom-produced 
Sensititre microtitre plates (Thermo Fisher Scientific, East Grinstead, UK) and MIC test 
strips (Liofilchem, Roseto degli Abruzzi, Italy), respectively, on 34 isolates chosen on the 
basis of resistance phenotype, year and country of isolation.
Total DNA extraction
Total DNA was extracted with the Wizard Genomic DNA Kit (Promega, Madison, WI, 
USA), the Maxwell 16-cell DNA purification kit (Promega, Madison WI) or the DNeasy 
Blood & Tissue Kit (Qiagen), in accordance with the manufacturer's recommendations.
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Whole-genome sequencing
High-throughput genome sequencing was carried out at the genomics platform of Institut 
Pasteur (n=107), or at the Wellcome Sanger Institute (n=9), or on Illumina platforms 
generating 92 to 295 bp paired-end reads, yielding a mean of 117-fold coverage (minimum 
13.5-fold, maximum 639-fold). Short-read sequence data were submitted to the European 
Nucleotide Archive (ENA) (http://www.ebi.ac.uk/ena), under study accession numbers 
PRJEB24611 and ERP021285, and the genome accession numbers are provided in 
Supplementary Table 1
Genomic sequence analyses
The genomic sequences were processed and analysed as previously described []. Briefly, for 
each sample, sequence reads were mapped against reference genome Vibrio cholerae O1 El 
Tor N16961 (GenBank accession numbers LT907989 and LT907990) using SMALT v0.7.4 
((http://www.sanger.ac.uk/science/tools/smalt-0) to produce a BAM file. Variants were 
detected with samtools mpileup [] version 0.1.19, with parameters “-d 1000 -DSugBf”, and 
bcftools [] version 0.1.19, to produce a BCF file of all variant sites. The bcftools variant 
quality score had to be greater than 50 (quality > 50) and mapping quality greater than 30 
(map_quality > 30). The majority base call was required to be present in at least 75% of 
reads mapping to the base, (ratio > 0.75), and the minimum mapping depth required was 4 
reads, at least two of which had to map to each strand (depth > 4, depth_strand > 2). A 
pseudogenome for each sample was constructed by substituting the base call at each site 
(variant and non-variant) in the BCF file in the reference genome. While this paper was 
under review, Bwire et al. [] published three genome sequences from Ugandan isolates 
belonging to the T13 clade. These three genome sequences were available as contig files and 
were added to the alignment with Snippy version 4.1.0 (https://github.com/tseemann/
snippy), using the “--ctgs” flag to call SNPs between the contigs and the reference genome. 
Short reads were assembled with SPAdes [] version 3.8.2 and annotated with Prokka [] 
version 1.5.
The code for the pipelines from the Sanger Institute used can be found here: https://
github.com/sanger-pathogens/vr-codebase
Phylogenetic analysis
Repetitive (insertion sequences and the TLC-RS1-CTX region) and recombinogenic (VSP-
II) regions were masked from the alignment []. Putative recombinogenic regions were 
detected and masked with Gubbins [] version 1.4.10. A maximum likelihood (ML) 
phylogenetic tree was built from an alignment of 9,986 chromosomal SNPs, with RAxML [] 
version 8.2.8 under the GTR model with 100 bootstraps.
BEAST [] version 1.10.1 was used to estimate time-resolved phylogenies for a spatially and 
temporally representative subset of 81 7PET isolates under the GTR nucleotide substitution 
model. We tested a combination of molecular clock and tree prior models to identify the best 
fit (Extended Data Table 1). Both path and stepping-stone sampling showed the best fit to be 
an uncorrelated relaxed clock (lognormal distribution of rates) model with a Bayesian 
skyline coalescent tree prior. Priors were kept at default values, with the exception of the 
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‘constant.popSize’ value, which was set to a lognormal distribution (initial value =1, mu =1, 
sigma=10) under the constant population coalescence tree prior. The choice of model had 
little impact on the dating of key nodes in this analysis (Extended Data Table 1). For each 
model, we ran three independent Markov chain Monte Carlo (MCMC) chains over 50 
million steps, sampling every 2000 steps. We used a burn-in of 5 million steps for each chain 
and then combined chains, resampling every 10,000 steps. The effective sample size (ESS) 
for all estimated parameters was greater than 200. We tested for an adequate temporal signal, 
using TempEst [] version 1.5, by calculating the linear regression between the root-to-tip 
distance and isolation date for each sample. We also performed 20 date-randomization tests 
with the R package TipDatingBeast [] to assess the ucld.mean parameter.
Extended Data
Extended data Figure 1. 
Geographic location of the sequenced V. cholerae O1 El Tor isolates and number of reported 
cholera cases. a, Geographic location of the 116 V. cholerae O1 El Tor isolates sequenced. 
The number of isolates collected per country is indicated. The three isolates collected in 
Jizan, Saudi Arabia (denoted by an asterisk) were from Yemeni refugees originating from 
Hajjah District. The map is a cropped version of the one available at: https://
commons.wikimedia.org/wiki/File:BlankMap-World.png. b, Number of cholera cases per 
country reported to the World Health Organisation (WHO) between 2014 and 2016. The 
total number of cholera cases reported to the WHO by the countries in panel b was 268,337. 
The maps were created using Paintmaps, a free online map generating tool (http://
www.paintmaps.com/).
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Extended data Figure 2. 
Assessment of the temporal signal within the dataset. a, Linear regression of the root-to-tip 
distance against sampling time obtained with TempEst [] using a maximum-likelihood 
phylogeny of 81 representative seventh pandemic V. cholerae O1 isolates (i.e., those used for 
the BEAST analysis). Bars on nodes indicate the precision of the isolation date (e.g., if only 
the year of isolation is known, the bar spans the entire year). b, Comparison of the 
ucld.mean parameter estimated from 20 date-randomisation BEAST experiments and the 
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original dataset. The rate for the correctly dated tree is shown in red. The median and 95% 
Bayesian credible interval for the ucld.mean parameter are provided.
Extended data Figure 3. 
Maximum clade credibility tree produced with BEAST [] for a subset of 81 representative 
isolates of the distal part of the genomic wave 3 (i.e., those with the ctxB7 allele). The nodes 
supported by posterior probability values ≥ 0.5 are indicated.
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Extended data Figure 4. 
Visualisation of the posterior distribution of trees from the BEAST MCMC analysis. The 
opacity of the branches is scaled according to the number of times a clade is seen in the 
distribution. There is high support for the East Africa/Yemen clade. The uncertainty in the 
placement of the node for the Indian/East African isolates is the reason for the low posterior 
support value for this node in Extended Data Figure 3.
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Extended data Figure 5. 
Multiple sequence alignment of VprA (VC_1320) with two-component response regulators. 
A non-synonymous mutation at position 89 of VC_1320 resulting in a D-to-N amino-acid 
change was associated with a phenotype of polymyxin B susceptibility.
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Extended Data Table 1
Summary of the Bayesian models used for BEAST [] 
analyses on a subset of 81 representative V. cholerae O1 
isolates of the distal part of the genomic wave 3.
tMRCA, time to the most recent common ancestor; UCLN, uncorrelated lognormal relaxed-
clock; HPD, highest posterior density region; MLE, marginal likelihood estimate.
Yemeni isolates tMRCA African/Yemeni isolates tMRCA
Model Median Upper 95% HPD Lower 95% HPD Median Upper 95% HPD Lower 95% HPD
Strict, Constant 2016.04 2016.34 2015.72 2014.14 2014.62 2013.59
Strict, Bayesian skyline 2016.03 2016.35 2015.71 2014.16 2014.63 2013.61
UCLN, Bayesian skyline 2016.05 2016.44 2015.67 2014.38 2014.86 2013.74
Model log MLE Path Sampling Rank log MLE Stepping Stone 
Sampling
Rank
Strict, Constant -5481314.81 3 -5481312.99 2
Strict, Bayesian skyline -5481314.47 2 -5481313.00 3
UCLN, Bayesian skyline -5481313.28 1 -5481311.50 1
Extended Data Table 2
Gene alteration frequencies in isolates susceptible or 
resistant to certain antibiotics.
FT, nitrofurantoin; POL, polymyxin B; *720 genomes with antimicrobial susceptibility 
testing data (this study and reference 2) or **106 genomes with antimicrobial susceptibility 
testing data (this study).
      Number (%) of isolates:
VCA_0637 FTS FTR
Wild-type 258 (94.2) 0 (0)
Genetic alteration 16 (5.8) 446 (100)
Total 274 446 720*
      Number (%) of isolates:
VC_0715 FTS FTR
Wild-type 264 (96.4) 5 (1.1)
Genetic alteration 10 (3.6) 441 (98.9)
Total 274 446 720*
      Number (%) of isolates:
VCA_0637 and VC_0715 FTS FTR
Wild-type 258 (94.2) 0 (0)
Genetic alteration 16 (5.8) 446 (100)
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Total 274 446 720*
      Number (%) of isolates:
VC_1320 POLS POLA
Wild-type 2 (3.1) 40 (97.6)
D89N 63 (96.9) 1(2.4)
Total 65 41 106**
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Figure 1. 
Geographic location of the sequenced V. cholerae O1 El Tor isolates and number of reported 
cholera cases. a, Aggregate number of suspected cholera cases per week in Yemen until 
December 31st, 2017 (http://yemeneoc.org/bi/), showing the two epidemic waves. The dates 
of the isolates sequenced in this study are shown under the epidemic curve. b, Geographic 
location of the 42 V. cholerae O1 El Tor isolates from Yemen. The three isolates collected in 
Saudi Arabia (denoted by asterisks) were obtained from Yemeni refugees from Hajjah 
District and are considered to be ‘Yemeni isolates’ throughout the manuscript. The number 
of cases per governorate is indicated according to reference 1. The governate map of Yemen 
was created using QGIS v2.16 (https://qgis.org) and the shape file approved for use by the 
UN Office for the Coordination of Humanitarian Affairs (OCHA) OCHA Yemen country 
office (https://data.humdata.org/dataset/yemen-admin-boundaries). The small inlay map was 
created using QGIS v2.16 using the Natural Earth basemap v4.0.0 (https://
www.naturalearthdata.com).
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Figure 2. 
Phylogenetic relatedness of the V. cholerae O1 El Tor isolates from the 2016-2017 epidemic 
in Yemen. a, Maximum likelihood phylogeny of 1,203 genomic sequences. M66 was used as 
an outgroup. The scale bar denotes substitutions per variable site (SNVs). Branches are 
coloured according to geographic location, inferred by stochastic mapping of the geographic 
origin of each isolate onto the tree. The inferred introduction events into Africa are indicated 
by the letter ‘T’. The sublineage labelled AME (Asia/Middle East) contains the most recent 
Middle Eastern isolates. b, Maximum clade credibility tree produced with BEAST for a 
subset of 81 representative isolates of the distal part of genomic wave 3 (i.e., those with the 
ctxB7 allele). Geographic location of the isolates is indicated in the same colours as in panel 
a. Selected nodes supported by posterior probability values ≥ 0.8 are shown. Acquisition of 
the polymyxin susceptibility-associated non-synonymous SNV in VC_1320 (vprA) is 
indicated. c. The geographic distribution of selected 7PET sublineages. An asterisk denotes 
data from reference 4. The date ranges shown for introductions are the 95% CI estimate of 
the MRCA in years. Dashed lines and the grey area in T13 indicate that the lineage was 
detected in East Africa before its appearance in the Yemen. This does not represent a precise 
route of transmission. The maps were created with Tableau Desktop version 10.1.5 using the 
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basemap from ©OpenStreetMap contributors (www.openstreetmap.org), available under the 
Open Database License.
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Table 1
Characteristics of the 2016-2017 Yemeni cholera epidemic strain
Species Vibrio cholerae
Serogroup, serotype and biotype O1, Ogawa, El Tor
Genomic wave 3
Genetic markers ctxB7, tcpACIRS101, rtxA°, VSP-IIΔ*
AMR profile POLS (1-2 mg/L), COLS (2-8 mg/L), O129R‡, NALR (64 - ≥ 256 mg/L), CIPDS (0.25-0.5 mg/L), 
FTR
Horizontally acquired AMR element, 
acquired AMR gene (AMR phenotype) ICEVchInd5/ICEVchBan5
Δ**
, dfrA1 (O129R)
Mutated chromosomal genes (AMR 
phenotype)
gyrA_S83I and parC_S85L (NALR, CIPDS)
nfsA_R169C and nfsB_Q5Stop (FTR)
AMR, antimicrobial resistance; POL, polymyxin B; COL, polymyxin E; NAL, nalidixic acid; CIP, ciprofloxacin; FT, nitrofurantoin; MIC range 
values are indicated in parentheses; R, S, and DS in uppercase indicate resistant, susceptible, and decreased susceptibility, respectively
Δ*
Deletion encompassing VC_0495-VC_0512 according to GenBank accession no. AE003852
Δ**
Deletion encompassing ICEVCHIND5_0011- ICEVCHIND5_0021 according to GenBank accession no. GQ463142
‡
cross-resistance to the vibriostatic agent O/129 and trimethoprim.
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